Sanofi: positive phase II data in MS

(CercleFinance.com) - Sanofi reports positive Phase II data for frexalimab, a new investigational anti-CD40L antibody, which shows a significant reduction in disease activity in patients with relapsing-remitting multiple sclerosis (MS).


Frexalimab met its primary endpoint, with an 89% reduction in new gadolinium-enhanced T1 brain lesions after 12 weeks of treatment, in the highest dose group, compared with placebo.

Sanofi plans to launch pivotal trials in the treatment of multiple sclerosis in early 2024, stressing that in this disease, highly effective and well-tolerated therapeutic options are still severely lacking.


Copyright (c) 2023 CercleFinance.com. All rights reserved.